tminederland

Oplosbare Antibody Stimulatieter onthuld door BOOST fosfotyrosine Proteomics

Chimère  antigeen  receptor  T-cellen (CAR-T-cellen) de toekomst in immunotherapie voor auto-immuunziekten?

Doelstelling:  CAR-T-celtherapie heeft een revolutie teweeggebracht in de behandeling van oncologische ziekten en recentelijk zijn mogelijke toepassingen bij auto-immuunziekten beschreven. De beoordeling heeft tot doel de beschikbare gegevens over de behandeling met CAR-T-cellen te integreren, met de nadruk op auto-immuunziekten, om de therapeutische vooruitgang en hun mogelijke toekomstige klinische toepasbaarheid bij auto-immuniteit te bepalen.

Materialen en methoden:  Er is gezocht in PubMed met de trefwoorden “Chimeric Antigen Receptor” en “CART cell”. De relevante documenten werden geselecteerd en de informatie werd kritisch bekeken.

Resultaten:  Bij de behandeling van auto-immuunziekten zijn in preklinische modellen drie verschillende cellulaire strategieën gebruikt, waaronder chimere antigeenreceptor T-cellen, chimere auto-antilichaamreceptor T-cellen en chimere antigeenreceptor in regulerende T-lymfocyten . Alle drie soorten therapie zijn effectief geweest. De mogelijke nadelige effecten daarin, het cytokine-afgiftesyndroom, cellulaire toxiciteit en neurotoxiciteit moeten altijd in gedachten worden gehouden.

Conclusies:  Hoewel er nog geen informatie over mensen beschikbaar is, laten preklinische modellen van CAR-T-cellen bij de behandeling van auto-immuunziekten veelbelovende resultaten zien, zodat ze in de toekomst een nuttige en effectieve therapie kunnen worden bij de behandeling van deze pathologieën.

Ovalbumine  Antigen -Specifieke Activatie van menselijke T-cel  -receptor  lijkt sterk op Oplosbare Antibody Stimulatieter onthuld door BOOST fosfotyrosine Proteomics

Activering van de T-celreceptor (TCR) leidt tot een netwerk van vroege signalering, voornamelijk georkestreerd door tyrosinefosforylering in T-cellen. De TCR wordt gewoonlijk geactiveerd met behulp van oplosbare anti-TCR-antilichamen, maar deze benadering is niet antigeenspecifiek. Als alternatief wordt aangenomen dat het activeren van de TCR met behulp van specifieke antigenen met een reeks bindingsaffiniteiten in de vorm van een peptide-major histocompatibiliteitscomplex (pMHC) meer fysiologisch is. Vanwege het ontbreken van grootschalige fosfotyrosine (pTyr) proteomische onderzoeken die anti-TCR-antilichamen en pMHC rechtstreeks vergelijken, blijft een uitgebreide definitie van deze geactiveerde toestanden echter raadselachtig.

Opheldering van het tyrosinefosfoproteoom met behulp van kwantitatieve pTyr-proteomics maakt een beter begrip mogelijk van de unieke kenmerken van deze activerende middelen en de rol van ligandbindingsaffiniteit op signalering. Hier passen we de latest opgerichte breedspectrumoptimalisatie van selectieve triggering (BOOST) toe om verstoringen in tyrosinefosforylering van menselijke TCR te onderzoeken, veroorzaakt door anti-TCR-antilichamen en pMHC. Onze gegevens laten zien dat pMHC-activering met hoge affiniteit ovalbumine (OVA) van de menselijke TCR een grotendeels vergelijkbare, zij het mogelijk sterkere, pTyr-gemedieerdesignaalregulerende as vergeleken met het anti-TCR-antilichaam. De signaleringsoutput die resulteert uit OVA pMHC-varianten correleert goed met hun zwakkere affiniteiten, waardoor affiniteit-afstembare controle van de signaalsterkte mogelijk is. Gezamenlijk bieden we een raamwerk voor het toepassen van BOOST om pTyr-gemedieerde signaalroutes van menselijke T-cellen te vergelijken die op een antigeenonafhankelijke en antigeenspecifieke manier zijn geactiveerd.

tminederland
tminederland

HIV-P24 antigen array kit

VArk-Lsx001 unit Ask for price
Description: Fourth-generation HIV immunoassays detect viral p24 protein in the blood.

HIV-1 p17-p24 recombinant antigen.

00172-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 p17-p24 recombinant antigen.

HIV-1 GAG P24 Recombinant Antigen

00111-V-01mg 0,1 mg
EUR 321
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV-1 GAG P24 Recombinant Antigen

00111-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV 1 p24 core recombinant antigen

00177-V-01mg 0,1 mg
EUR 321
Description: HIV 1 p24 core recombinant antigen.

HIV 1 p24 core recombinant antigen

00177-V-1000ug 1000 ug
EUR 1539
Description: HIV 1 p24 core recombinant antigen.

HIV 1 p24 core recombinant antigen.

00177-V-100ugvial 100ug/vial
EUR 150
Description: HIV 1 p24 core recombinant antigen.

HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations)

0801200 5 X 96T
EUR 2563

HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations)

801200 5 X 96 Determinations
EUR 2330

HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations)

801008 5 X 96 Determinations
EUR 2386

HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations)

0801008 5 X 96T
EUR 2505

Human HIV(1+2 antibodies plus p24 antigen (4th Generation) ELISA Kit

EH4101 96T
EUR 571.5
Description: Method of detection: Qualitative ;Reacts with: Homo sapiens;Sensitivity: Qualitative

HIV-1 p24 ELISA Kit

Z7040001 1 kit
EUR 752

HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

00111-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV-1 p17/24/gp120 antigen

00169-V-01mg 0,1 mg
EUR 321
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

HIV-1 p17/24/gp120 antigen

00169-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

HIV-1 intergase antigen

00199-V-01mg 0,1 mg
EUR 321
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase).

HIV-1 intergase antigen

00199-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase).

HIV-1 p24 Antibody

20-abx137062
  • EUR 427.20
  • EUR 627.60
  • 0.5 mg
  • 1 mg

HIV-1 p24 Antibody

7313-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.

HIV-1 p24 Antibody

7313-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.

HIV-1 p24 Antibody

abx021869-1mg 1 mg
EUR 794.4

HIV-1 p24 Antibody

abx021870-1mg 1 mg
EUR 760.8

HIV-1 p24 Antibody

abx021871-1mg 1 mg
EUR 794.4

HIV-1 p24 Antibody

abx021872-1mg 1 mg
EUR 794.4

HIV-1 p24 Antibody

abx021873-1mg 1 mg
EUR 794.4

HIV-1 p24 Antibody

abx021882-1mg 1 mg
EUR 1178.4

HIV-1 p24 Antibody

abx021883-1mg 1 mg
EUR 1220.4

HIV-1 p24 Antibody

abx021886-1mg 1 mg
EUR 1220.4

HIV-1 p24 Antibody

abx021887-1mg 1 mg
EUR 1220.4

HIV-1 p24 Antibody

abx021888-1mg 1 mg
EUR 1220.4

HIV-1 p24 Antibody

abx023027-1ml 1 ml
EUR 693.6

HIV-1 p24 Antibody

abx023925-1mg 1 mg
EUR 828

HIV-1 p24 Antibody

abx023926-1mg 1 mg
EUR 828

HIV-1 p24

E5-00024 1mg
EUR 1152

HIV-1 p24

E62H002 100ug
EUR 458.4

HIV-1 tat recombinant antigen

00110-V-01mg 0,1 mg
EUR 321
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 tat recombinant antigen

00110-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 nef recombinant antigen

00112-V-01mg 0,1 mg
EUR 321
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 nef recombinant antigen

00112-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 gag recombinant antigen

8934 100 ug
EUR 542.86
Description: This is HIV-1 gag recombinant antigen for ELISA,WB.

HIV-1 nef recombinant antigen

8941 100 ug
EUR 477.6
Description: This is HIV-1 nef recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen,

00170-V-01mg 0,1 mg
EUR 321
Description: HIV-1 gp41 recombinant antigen.

HIV-1 gp41 recombinant antigen,

00170-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 gp41 recombinant antigen.

HIV-1 gp41 recombinant antigen

8908 100 ug
EUR 673.36
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen

8933 100 ug
EUR 477.6
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen

9000 100 ug
EUR 484.13
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen

9001 100 ug
EUR 484.13
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen.

00170-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 gp41 recombinant antigen.

HIV p24 Antibody

abx021867-1mg 1 mg
EUR 1612.8

HIV p24 Antibody

abx021868-1mg 1 mg
EUR 1612.8

HIV-1 p17/24/gp120-gp41 recombinant antigen,

00168-V-01mg 0,1 mg
EUR 321
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen.

HIV-1 p17/24/gp120-gp41 recombinant antigen,

00168-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen.

HIV-1 p17/24/gp120-gp41 recombinant antigen.

00168-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen.

HIV 1 envelope recombinant antigen

00176-V-01mg 0,1 mg
EUR 321
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

HIV 1 envelope recombinant antigen

00176-V-1000ug 1000 ug
EUR 1539
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

ToX Antigen (P24,GRA1)

E61Y00305 1mg
EUR 840

HIV-1 p24 Antibody (HRP)

abx023029-1ml 1 ml
EUR 886.8

HIV-1 p24 Antibody [8G9]

PM-6335-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [8G9]

PM-6335-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4]

PM-6585-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4]

PM-6585-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 env gp41 recombinant antigen

00113-V-01mg 0,1 mg
EUR 321
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-1 env gp41 recombinant antigen

00113-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-1 p24 Antibody (FITC)

abx021884-100ug 100 ug
EUR 886.8

HIV-1 p24 Antibody (FITC)

abx023026-1ml 1 ml
EUR 678

HIV 1 / 2 p24 Antibody

abx021866-1mg 1 mg
EUR 1212

HIV 1 / 2 p24 Antibody

abx021890-1mg 1 mg
EUR 1212

HIV-1 gp41 Long recombinant antigen,

00171-V-01mg 0,1 mg
EUR 321
Description: HIV-1 gp41 Long recombinant antigen.

HIV-1 gp41 Long recombinant antigen,

00171-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 gp41 Long recombinant antigen.

HIV-1 gp41 Long recombinant antigen.

00171-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 gp41 Long recombinant antigen.

HIV-1 p24 Antibody (Biotin)

abx023028-1ml 1 ml
EUR 794.4

Polyclonal HIV-1 p24 Antibody

APR11116G 0.1 mg
EUR 790.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human HIV-1 p24 . This antibody is tested and proven to work in the following applications:

HIV-1 p24 Protein

20-abx261886
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

HIV-1 p24 Protein

abx169032-1mg 1 mg
EUR 661.2

HIV-1 p24 Protein

abx061424-05mg 0.5 mg
EUR 886.8

HIV-1, p24 Protein

abx069857-1mg 1 mg
EUR 1888.8

HIV-1 Gag p24

05-005 50 ug
EUR 434.4
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur.

HIV-1 Gag p24

05-006 250 ug
EUR 1154.4
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur.

Recombinant HIV-1 p24

7-07603 100µg Ask for price

Recombinant HIV-1 p24

7-07604 500µg Ask for price

Recombinant HIV-1 p24

7-07605 1000µg Ask for price

HIV 1 p24 Protein

abx060589-1mg 1 mg
EUR 1545.6

HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

00169-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

HIV 1, 2 envelope recombinant antigen

00175-V-01mg 0,1 mg
EUR 321
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV 1, 2 envelope recombinant antigen

00175-V-1000ug 1000 ug
EUR 1539
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV-1 reverse transcriptase recombinant antigen

00198-V-01mg 0,1 mg
EUR 321
Description: HIV-1 reverse transcriptase recombinant antigen.

HIV-1 reverse transcriptase recombinant antigen

00198-V-1000ug 1000 ug
EUR 1539
Description: HIV-1 reverse transcriptase recombinant antigen.

HIV-1 reverse transcriptase recombinant antigen.

00198-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 reverse transcriptase recombinant antigen.

Feline Immunodeficiency Virus p24 Antigen (FIV p24) Antibody

abx411336-02mg 0.2 mg
EUR 710.4

Feline Immunodeficiency Virus p24 Antigen (FIV p24) Antibody

abx412988-2ml 2 ml
EUR 727.2

HIV Type-1 p24 Antibody

V2344-100UG 100 ug
EUR 349.3
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.

HIV Type-1 p24 Antibody

V2344-20UG 20 ug
EUR 153.3
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.

HIV Type-1 p24 Antibody

V2344CF488-100T 100 Tests
EUR 349.3
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.

HIV Type-1 p24 Antibody

V2344SAF-100UG 100 ug
EUR 349.3
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.

HIV-2 gp32 recombinant antigen

00173-V-01mg 0,1 mg
EUR 321
Description: HIV-2 gp32 recombinant antigen. .

HIV-2 gp32 recombinant antigen

00173-V-1000ug 1000 ug
EUR 1539
Description: HIV-2 gp32 recombinant antigen. .

HIV-2 gp36 recombinant antigen

8911 100 ug
EUR 673.36
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB.

HIV-2 gp36 recombinant antigen

8949 100 ug
EUR 529.8
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB.

HIV-2 gp36 recombinant antigen

9003 100 ug
EUR 484.13
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB.

HIV-2 gp32 recombinant antigen. .

00173-V-100ugvial 100ug/vial
EUR 150
Description: HIV-2 gp32 recombinant antigen. .

HIV type 1 P24

DAG1520 100 µg
EUR 972

HIV-1 p24 Antibody [8G9] (HRP)

PM-6335-HRP-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [8G9] (HRP)

PM-6335-HRP-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4] (HRP)

PM-6585-HRP-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4] (HRP)

PM-6585-HRP-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [8G9] (biotin)

PM-6335-biotin-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [8G9] (biotin)

PM-6335-biotin-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4] (biotin)

PM-6585-biotin-002mg 0.02 mg
EUR 206.18
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4] (biotin)

PM-6585-biotin-01mg 0.1 mg
EUR 523.7
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV type O envelope antigen

00178-V-01mg 0,1 mg
EUR 321
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence.

HIV type O envelope antigen

00178-V-1000ug 1000 ug
EUR 1539
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence.

HIV 2 gp36 envelope antigen

00180-V-01mg 0,1 mg
EUR 321
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36.

HIV 2 gp36 envelope antigen

00180-V-1000ug 1000 ug
EUR 1539
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36.

Polyclonal HIV-1 p24 Antibody [7F4]

APR11117G 0.1 mg
EUR 790.8
Description: A polyclonal antibody raised in Mouse that recognizes and binds to Human HIV-1 p24 [7F4] . This antibody is tested and proven to work in the following applications:

HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

00175-V-100ugvial 100ug/vial
EUR 150
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV-2 GP 36 Recombinant Antigen

00114-V-01mg 0,1 mg
EUR 321
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

HIV-2 GP 36 Recombinant Antigen

00114-V-1000ug 1000 ug
EUR 1539
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

HIV-1 p24, His tag

E410A26-20 20μg
EUR 520.8

HIV-1 p24 Core Protein

20-abx260141
  • EUR 1062.00
  • EUR 410.40
  • EUR 1646.40
  • 0.5 mg
  • 100 ug
  • 1 mg

Mouse antibody for HIV-1 p24

1941 100 ug
EUR 399.3
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

Mouse antibody for HIV-1 p24

1946 100 ug
EUR 425.4
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

Mouse antibody for HIV-1 p24

1947 100 ug
EUR 425.4
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

Mouse antibody for HIV-1 p24

1948 100 ug
EUR 425.4
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

Mouse antibody for HIV-1 p24

1949 100 ug
EUR 425.4
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA.

Recombinant HIV-1 p24 Core

7-07597 100µg Ask for price

Recombinant HIV-1 p24 Core

7-07598 500µg Ask for price

Recombinant HIV-1 p24 Core

7-07599 1000µg Ask for price

QuickTiter HIV Lentivirus Quantitation Kit (p24 ELISA)

VPK-108-H 96 assays
EUR 866.4
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation.

QuickTiter HIV Lentivirus Quantitation Kit (p24 ELISA)

VPK-108-H-5 5 x 96 assays
EUR 3560.4
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation.

Recombinant HIV-1 p24 , 24kDa

7-07621 2µg Ask for price

Recombinant HIV-1 p24 , 24kDa

7-07622 10µg Ask for price

Recombinant HIV-1 p24 , 24kDa

7-07623 100µg Ask for price

HIV-1 p24 Recombinant Protein

53-341 0.01 mg
EUR 789.9
Description: HIV-1 p24 Recombinant Protein

HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

00112-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

00113-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV -2 env gp36 recombinant antigen

00179-V-01mg 0,1 mg
EUR 321
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702.

HIV -2 env gp36 recombinant antigen

00179-V-1000ug 1000 ug
EUR 1539
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702.

HIV type 1 P24 [GST]

DAG1516 100 µg
EUR 774

HIV type 1 P24 [His]

DAG1518 100 µg
EUR 774

HIV type 1 P24 [His]

DAG1799 50 ug
EUR 2017.2

HIV type 1 P24 [His]

DAG2375 100 µg
EUR 868.8

HIV type 1 P24 [His]

DAG2377 100 µg
EUR 868.8

HIV-1 tat recombinant antigen full length 15 kDa

00110-V-100ugvial 100ug/vial
EUR 150
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 p24 Immune Complex Dissociation Kit

Z7040009 1 kit
EUR 122

HIV type 1 p24 [FITC]

DAGH004 50 Tests
EUR 1112.4

HTLV-I p24 core recombinant antigen

00204-V-01mg 0,1 mg
EUR 321
Description: HLTV-I p24 core recombinant antigen.

HTLV-I p24 core recombinant antigen

00204-V-1000ug 1000 ug
EUR 1539
Description: HLTV-I p24 core recombinant antigen.

HLTV-I p24 core recombinant antigen.

00204-V-100ugvial 100 ug/vial
EUR 150
Description: HLTV-I p24 core recombinant antigen.

HIV type 1 P24 [Biotin]

DAG1519 100 µg
EUR 972

Feline Immunodeficiency Virus p24 gag Antigen (FIV p24 gag) Antibody

abx413943-025mg 0.25 mg
EUR 811.2

HIV-1 gag p17, p24 Protein

20-abx260277
  • EUR 1062.00
  • EUR 410.40
  • EUR 1930.80
  • 0.5 mg
  • 100 ug
  • 1 mg

HIV-1 p24, 24 kDa Protein

20-abx263118
  • EUR 1562.40
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

Recombinant HIV-1 gag p17, p24

7-07675 100µg Ask for price

Recombinant HIV-1 gag p17, p24

7-07676 500µg Ask for price

Recombinant HIV-1 gag p17, p24

7-07677 1000µg Ask for price

Felis p27 core antigen ELISA Kit

ELA-E1491FELA-E 96 Tests
EUR 1113.6

HIV-1 p24 Core, Sf9 Protein

20-abx260012
  • EUR 2815.20
  • EUR 493.20
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

Mouse Monoclonal Anti- HIV-1 p24 IgG

AB-15210 100 ug
EUR 416.4

Toxoplasma gondii P24 (GRA1) recombinant antigen

00207-V-01mg 0,1 mg
EUR 321
Description: Toxoplasma gondii P24 (GRA1) recombinant antigen

Toxoplasma gondii P24 (GRA1) recombinant antigen

00207-V-1000ug 1000 ug
EUR 1539
Description: Toxoplasma gondii P24 (GRA1) recombinant antigen

Toxoplasma gondii P24 (GRA1) recombinant antigen

00207-V-100ugvial 100ug/vial
EUR 150
Description: Toxoplasma gondii P24 (GRA1) recombinant antigen

HIV-1 gp120 and gp41 Chimeric Antigen (16 kDa, Capture)

DAGF-220 1mg
EUR 817.2

HIV-1 gp120 and gp41 Chimeric Antigen (8 kDa, Capture)

DAGF-222 1mg
EUR 817.2

HIV-1 gp120 and gp41 Chimeric Antigen (45 kDa, Capture)

DAGF-224 1mg
EUR 817.2

Recombinant HIV-1 p24 His Tag

7-07606 5µg Ask for price

Recombinant HIV-1 p24 His Tag

7-07607 20µg Ask for price

Recombinant HIV-1 p24 His Tag

7-07608 1mg Ask for price

Recombinant HIV-1 p24 Core, Sf9

7-07602 100µg Ask for price

Recombinant HIV-1 p24 Core, Sf9

7-07600 2µg Ask for price

Recombinant HIV-1 p24 Core, Sf9

7-07601 10µg Ask for price

HIV-1 gp120 and gp41 Chimeric Antigen (43 kDa, Detection)

DAGF-223 1mg
EUR 817.2

HIV-1 p24, Biotin Labeled Protein

20-abx260358
  • EUR 1496.40
  • EUR 560.40
  • EUR 2364.00
  • 0.5 mg
  • 100 ug
  • 1 mg

p24-HIV(p24/661) Antibody

BNCA0661-250 250uL
EUR 459.6
Description: Primary antibody against p24-HIV(p24/661), APC conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC800661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC800661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC810661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC810661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC940661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC940661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC700661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC700661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC880661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC880661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC050661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC050661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC040661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC040661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC400661-100 100uL
EUR 238.8
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody

BNC400661-500 500uL
EUR 652.8
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL

Bilaterale anterior cerebrale slagader occlusie na CD19- en BCMA-gerichte chimere  antigeen  receptor  van T-celtherapie voor een patiënt myeloom

Chimere antigeenreceptor T (CAR-T)-celtherapie is een veelbelovende behandeling voor recidiverend/refractair multipel myeloom (RRMM). In ons vorige rapport was CD19- en BCMA-gerichte gelijktijdige toediening van CAR-T geassocieerd met een hoog responspercentage. Hoewel cytokine launch syndrome (CRS) en neurotoxiciteit frequente complicaties zijn na behandeling met CAR-T, wordt een herseninfarct zelden gerapporteerd als een CAR-T-gerelateerde complicatie. We rapporteerden een 73-jarige vrouwelijke MM-patiënt die CD19- en BCMA-gerichte CAR-T ontving voor refractaire ziekte.

Haar ziekte reageerde op CAR-T- therapie, maar ze ontwikkelde neurologische symptomen na CRS. Craniale CT en MRI toonden meerdere herseninfarcten en bilaterale anterieure cerebrale arterie (ACA) occlusie aan. We suggereren dat een ander herseninfarct dan CAR-T-gerelateerde neurotoxiciteit de onderliggende oorzaak is van abnormale neuropsychologische symptomen, en diagnostische beeldvormingstests moeten actief worden uitgevoerd om ischemische cerebrovasculaire gebeurtenissen uit te sluiten.

Het intracellulaire domein van CD40 is een krachtige Costimulatoire Ingredient in chimère  Antigen  Receptoren

De co-stimulerende domeinen die zijn ingebouwd in chimere antigeenreceptoren (CAR’s) van de tweede generatie en de derde generatie, hebben een sterke invloed op de functie van CAR-T-cellen . Hier hebben we CAR’s van de tweede generatie en de derde generatie onderzocht die het signaleringsdomein van de CD40-receptor herbergen als een nieuw costimulerend component in vergelijking met vergelijkbare CAR’s die het 4-1BB-domein dragen . In CAR’s van beide generaties was CD40 krachtiger dan 4-1BB bij het triggeren van de NF-KB-signaleringsroute.

In humane T-cellen van 2 donoren was CD40 vergelijkbaar met 4-1BB bij het opreguleren van co-stimulerende en activatiemarkers, het induceren van pro-inflammatoire cytokinesecretie en het mediëren van het doden van doelwitcellen. Interessant genoeg waren er duidelijk verschillen in het responspatroon van T-cellen van de 2 donoren met betrekking tot CD40 en 4-1BB. We concluderen dat in menselijke T-cellen het CD40- signaleringsdomein een krachtig co-stimulerend component is in CAR’s van zowel de tweede generatie als de derde generatie.

Een systematische herziening van de rol van chimere  Antigeen  Receptor  T (CAR-T) celtherapie bij de behandeling van solide tumoren

Chimere antigeenreceptor T (CAR-T) celtherapie maakt gebruik van de eigen T-lymfocyten van de patiënt die zijn ontworpen om kankercellen aan te vallen. Het is door de Meals and Drug Administration (FDA) goedgekeurd voor verschillende hematologische maligniteiten en wordt momenteel geëvalueerd bij solide kankers in vroege fase-onderzoeken. We deden een systematische evaluate bestaande uit 15 prospectieve klinische onderzoeken (n = 159) die CAR-T-cellen in solide kankers evalueerden . Vroege fase-onderzoeken toonden veelbelovende responspercentages bij ovariumepitheelkanker (100%), humaan epidermale groeifactorreceptor  (HER2)-positief sarcoom (67%) , epidermale groeifactorreceptor (EGFR)-positieve galwegkanker (65%), gevorderde maag-/pancreaskanker (82%), hepatocellulair carcinoom (67%),en colorectale kanker (70%) .

De mediane algehele respons voor alle maligniteiten was 62% (bereik 17%-100%) . De mediane progressievrije overleving en de totale overleving werden in de meeste onderzoeken niet bereikt. Cytokine-afgiftesyndroom werd gezien bij slechts één patiënt met cholangiocarcinoom die EGFR-specifieke CAR-T-celtherapie kreeg. Hoewel de overlevingsgegevens nog steeds niet volgroeid zijn, liet CAR-T-celtherapie bij solide maligniteiten bemoedigende responspercentages zien en werd goed verdragen.

Verschillen in lymfoompatiënten tussen chimeer  antigeen  receptor  van T-cel therapeutische proeven en bevolking

Chimere antigeenreceptor (CAR)-T-celtherapieën lijken veelbelovende behandelingen te zijn voor non-Hodgkin- en B-cellymfoom. Verschillende CAR-T-therapieën die zijn goedgekeurd door de Amerikaanse Meals and Drug Administration, zijn echter alleen op werkzaamheid getest in relatief weinig klinische onderzoeken met een enkele arm met kleine steekproefomvang. We probeerden de verschillen tussen patiënten in deze onderzoeken en de algemene populatie van patiënten met non-Hodgkin- en B-cellymfoom te onderzoeken. Vijfhonderdtweeëntwintig patiënten uit 15 CAR-T-onderzoeken gevonden in een systematische evaluate en 417.492 patiënten uit de Surveillance, Epidemiology, and Finish Outcomes (SEER) Program-database werden vergeleken.

De deelnemers aan de CAR-T-studie leken jonger (46,7% jonger dan 70 jaar vs. 42,2%) , meer mannelijk (68,0% vs. 55,7%) en werden gedurende een kortere periode gevolgd in vergelijking met patiënten in de SEER-populatie (gemiddelde [M] 45,6 maanden, 95% betrouwbaarheidsinterval [BI] 17,7 tot 63,three maanden follow-up vs. M 57,1 maanden, 95% BI 57,Zero tot 57,three maanden overleving). Deelnemers aan de CAR-T-studie kunnen aanzienlijk verschillen van de algemene populatie van patiënten met non-Hodgkin- en B-cellymfoom . De effectiviteit van CAR-T-therapieën bij de algemene populatie van lymfoompatiënten kan verschillen van de effectiviteit die is aangetoond in onderzoeken. Nieuw gecreëerde CAR-T-patiëntenregisters zijn essentieel om de effectiviteit van de therapieën op populatieniveau huge te stellen.

 

Tie2 Kinase Inhibitor

B1338-5 each
EUR 314.4

Tie2 kinase inhibitor

A5979-100 100 mg
EUR 1452
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 kinase inhibitor

A5979-25 25 mg
EUR 477.6
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 kinase inhibitor

A5979-5 5 mg
EUR 199.2
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 kinase inhibitor

A5979-5.1 10 mM (in 1mL DMSO)
EUR 536.4
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 kinase inhibitor

E1KS1577 10mg
EUR 1849.2

K252A (Kinase inhibitor)

SIH-455-100UG 100 µg
EUR 157.2
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO.

K252A (Kinase inhibitor)

SIH-455-1MG 1 mg
EUR 358.8
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO.

K252B (Kinase inhibitor)

SIH-456-100UG 100 µg
EUR 218.4
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml).

K252B (Kinase inhibitor)

SIH-456-1MG 1 mg
EUR 682.8
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml).

MAPKII Kinase Inhibitor

abx076811-1mg 1 mg
EUR 376.8

Sorafenib (Raf-1 kinase inhibitor)

SIH-476-10MG 10 mg
EUR 145.2
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml).

Sorafenib (Raf-1 kinase inhibitor)

SIH-476-50MG 50 mg
EUR 346.8
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml).

Tyrosine kinase inhibitor

HY-10421 25mg
EUR 459.6

Dasatinib (Kinase inhibitor)

SIH-440-25MG 25 mg
EUR 238.8
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ).

Dasatinib (Kinase inhibitor)

SIH-440-5MG 5 mg
EUR 160.8
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ).

IKK-? Kinase Inhibitor II

1811-1 each
EUR 189.6

IKK-? Kinase Inhibitor II

1811-5 each
EUR 574.8

RIP2 kinase inhibitor 2

HY-19761 50mg
EUR 2539.2

PP1 (Src kinase inhibitor)

SIH-469-25MG 25 mg
EUR 742.8
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol.

PP1 (Src kinase inhibitor)

SIH-469-5MG 5 mg
EUR 246
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol.

PP2 (Src kinase inhibitor)

SIH-470-25MG 25 mg
EUR 884.4
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml).

PP2 (Src kinase inhibitor)

SIH-470-5MG 5 mg
EUR 279.6
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml).

C16 (PKR kinase inhibitor)

SIH-498-25MG 25 mg
EUR 420
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml .

C16 (PKR kinase inhibitor)

SIH-498-5MG 5 mg
EUR 164.4
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml .

Midostaurin (Kinase inhibitor)

SIH-468-1MG 1 mg
EUR 205.2
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml).

Midostaurin (Kinase inhibitor)

SIH-468-5MG 5 mg
EUR 608.4
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml).

Aurora Kinase Inhibitor 3

HY-112373 1mg
EUR 198

6BIO (PDK1 kinase inhibitor)

SIH-422-25MG 25 mg
EUR 474
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol.

6BIO (PDK1 kinase inhibitor)

SIH-422-5MG 5 mg
EUR 178.8
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol.

LYS6K2 (S6 kinase inhibitor)

SIH-462-25MG 25 mg
EUR 582
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming).

LYS6K2 (S6 kinase inhibitor)

SIH-462-5MG 5 mg
EUR 205.2
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming).

Aurora Kinase Inhibitor III

B7947-.5 500 µg
EUR 141.6
Description: Aurora Kinase Inhibitor III

Aurora Kinase Inhibitor III

B7947-1 1 mg
EUR 214.8
Description: Aurora Kinase Inhibitor III

Aurora Kinase Inhibitor III

B7947-5 5 mg
EUR 714
Description: Aurora Kinase Inhibitor III

KT5720 (PKA kinase inhibitor)

SIH-457-100UG 100 µg
EUR 246
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml.

KT5720 (PKA kinase inhibitor)

SIH-457-500UG 500 µg
EUR 682.8
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml.

ml167 (Clk4 kinase inhibitor)

SIH-505-25MG 25 mg
EUR 608.4
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear .

ml167 (Clk4 kinase inhibitor)

SIH-505-5MG 5 mg
EUR 205.2
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear .

GW2580 (cFMS kinase inhibitor)

SIH-449-25MG 25 mg
EUR 447.6
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) .

GW2580 (cFMS kinase inhibitor)

SIH-449-5MG 5 mg
EUR 168
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) .

PD98059 (MEK kinase inhibitor)

SIH-466-25MG 25 mg
EUR 514.8
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml).

PD98059 (MEK kinase inhibitor)

SIH-466-5MG 5 mg
EUR 184.8
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml).

AZD6244 (ERK kinase inhibitor)

SIH-495-25MG 25 mg
EUR 716.4
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).

AZD6244 (ERK kinase inhibitor)

SIH-495-5MG 5 mg
EUR 252
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).

SRPIN340 (SR kinase inhibitor)

SIH-514-25MG 25 mg
EUR 481.2
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl.

SRPIN340 (SR kinase inhibitor)

SIH-514-5MG 5 mg
EUR 178.8
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl.

AG1296 (PDGFR kinase inhibitor)

SIH-426-25MG 25 mg
EUR 608.4
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane.

AG1296 (PDGFR kinase inhibitor)

SIH-426-5MG 5 mg
EUR 205.2
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane.

SU1498 (VEGFR kinase inhibitor)

SIH-480-25MG 25 mg
EUR 447.6
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO .

SU1498 (VEGFR kinase inhibitor)

SIH-480-5MG 5 mg
EUR 169.2
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO .

PD325901 (MEK kinase inhibitor)

SIH-507-25MG 25 mg
EUR 554.4
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO.

PD325901 (MEK kinase inhibitor)

SIH-507-5MG 5 mg
EUR 205.2
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO.

PHA 665752 (MET kinase inhibitor)

SIH-421-25MG 25 mg
EUR 696
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. .

PHA 665752 (MET kinase inhibitor)

SIH-421-5MG 5 mg
EUR 231.6
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. .

A83 01 (ALK kinase inhibitor)

SIH-423-25MG 25 mg
EUR 514.8
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO.

A83 01 (ALK kinase inhibitor)

SIH-423-5MG 5 mg
EUR 187.2
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO.

CID 2011756 (PKD kinase inhibitor)

SIH-438-25MG 25 mg
EUR 514.8
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO.

CID 2011756 (PKD kinase inhibitor)

SIH-438-5MG 5 mg
EUR 184.8
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO.

KT 5823 (PKG kinase inhibitor)

SIH-458-100UG 100 µg
EUR 246
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).

KT 5823 (PKG kinase inhibitor)

SIH-458-500UG 500 µg
EUR 682.8
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).

NPC 15437 (PKC kinase inhibitor)

SIH-464-1MG 1 mg
EUR 205.2
Description: The substance NPC 15437 is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in water, DMSO or methanol.

NPC 15437 (PKC kinase inhibitor)

SIH-464-5MG 5 mg
EUR 447.6
Description: The substance NPC 15437 is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in water, DMSO or methanol.

Src I1 (Src kinase inhibitor)

SIH-478-25MG 25 mg
EUR 399.6
Description: The substance Src I1 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (5 mg/ml).

Src I1 (Src kinase inhibitor)

SIH-478-5MG 5 mg
EUR 158.4
Description: The substance Src I1 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (5 mg/ml).

GF109203X (PKC kinase inhibitor)

SIH-447-10MG 10 mg
EUR 306
Description: The substance GF109203X is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is red solid which is soluble in dimethyl formamide or DMSO (10 mg/ml, warm to 40°C and vortex well).

GF109203X (PKC kinase inhibitor)

SIH-447-1MG 1 mg
EUR 178.8
Description: The substance GF109203X is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is red solid which is soluble in dimethyl formamide or DMSO (10 mg/ml, warm to 40°C and vortex well).

Auranofin (IKK kinase inhibitor)

SIH-493-50MG 50 mg
EUR 178.8
Description: The substance Auranofin is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (5 mg/ml) or 100% ethanol (4 mg/ml).

LY364947 (ALK5 kinase inhibitor)

SIH-504-25MG 25 mg
EUR 474
Description: The substance LY364947 is a alk5 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow to brown solid which is soluble to 100 mM in DMSO.

LY364947 (ALK5 kinase inhibitor)

SIH-504-5MG 5 mg
EUR 184.8
Description: The substance LY364947 is a alk5 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow to brown solid which is soluble to 100 mM in DMSO.

p21/Cyclin-Dependent Kinase Inhibitor 1

MO47036 100 ul
EUR 418.8

AG 1478 (EGFR kinase inhibitor)

SIH-425-25MG 25 mg
EUR 474
Description: The substance AG 1478 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light yellow solid which is soluble in DMSO (10 mg/ml).

AG 1478 (EGFR kinase inhibitor)

SIH-425-5MG 5 mg
EUR 184.8
Description: The substance AG 1478 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light yellow solid which is soluble in DMSO (10 mg/ml).

AG 1517 (EGFR kinase inhibitor)

SIH-427-25MG 25 mg
EUR 541.2
Description: The substance AG 1517 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO.

AG 1517 (EGFR kinase inhibitor)

SIH-427-5MG 5 mg
EUR 192
Description: The substance AG 1517 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO.

AG 879 (NGFR kinase inhibitor)

SIH-429-25MG 25 mg
EUR 514.8
Description: The substance AG 879 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in 100% ethanol (25 mg/ml) or DMSO (25 mg/ml).

AG 879 (NGFR kinase inhibitor)

SIH-429-5MG 5 mg
EUR 182.4
Description: The substance AG 879 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in 100% ethanol (25 mg/ml) or DMSO (25 mg/ml).

Bml 277 (CHK2 kinase inhibitor)

SIH-436-10MG 10 mg
EUR 210
Description: The substance Bml 277 is a chk2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (20 mg/ml).

Bml 277 (CHK2 kinase inhibitor)

SIH-436-50MG 50 mg
EUR 608.4
Description: The substance Bml 277 is a chk2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (20 mg/ml).

GW 441756 (NGFR kinase inhibitor)

SIH-450-10MG 10 mg
EUR 279.6
Description: The substance GW 441756 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of >99. The pure substance is red solid which is soluble to 15 mM in DMSO.

GW 441756 (NGFR kinase inhibitor)

SIH-450-50MG 50 mg
EUR 877.2
Description: The substance GW 441756 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of >99. The pure substance is red solid which is soluble to 15 mM in DMSO.

LFM A13 (BTK kinase inhibitor)

SIH-461-25MG 25 mg
EUR 481.2
Description: The substance LFM A13 is a btk kinase inhibitor. It is synthetically produced and has a purity of ?97%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml).

LFM A13 (BTK kinase inhibitor)

SIH-461-5MG 5 mg
EUR 178.8
Description: The substance LFM A13 is a btk kinase inhibitor. It is synthetically produced and has a purity of ?97%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml).

Y 27632 (ROCK kinase inhibitor)

SIH-486-1MG 1 mg
EUR 178.8
Description: The substance Y 27632 is a rock kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to pale yellow powder which is soluble in DMSO (25 mg/ml), methanol (25 mg/ml), acetonitrile (<1 mg/ml), dioxan (<1 mg/ml), water (very soluble.

Y 27632 (ROCK kinase inhibitor)

SIH-486-5MG 5 mg
EUR 393.6
Description: The substance Y 27632 is a rock kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to pale yellow powder which is soluble in DMSO (25 mg/ml), methanol (25 mg/ml), acetonitrile (<1 mg/ml), dioxan (<1 mg/ml), water (very soluble.

AG 494 (EGFR kinase inhibitor)

SIH-491-10MG 10 mg
EUR 178.8
Description: The substance AG 494 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (25 mg/ml) or 100% ethanol (25 mg/ml).

AG 494 (EGFR kinase inhibitor)

SIH-491-50MG 50 mg
EUR 481.2
Description: The substance AG 494 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (25 mg/ml) or 100% ethanol (25 mg/ml).

SR 3576 (JNK3 kinase inhibitor)

SIH-513-5MG 5 mg
EUR 298.8
Description: The substance SR 3576 is a jnk3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off white solid which is soluble to 100 mM in DMSO.

CHIR99021 (GSK3? kinase inhibitor)

SIH-437-1MG 1 mg
EUR 151.2
Description: The substance CHIR99021 is a gsk3? kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light brown solid which is soluble to 20 mM in DMSO.

CHIR99021 (GSK3? kinase inhibitor)

SIH-437-5MG 5 mg
EUR 246
Description: The substance CHIR99021 is a gsk3? kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light brown solid which is soluble to 20 mM in DMSO.

Gefitinib (EGFR Kinase inhibitor)

SIH-445-250MG 250 mg
EUR 360
Description: The substance Gefitinib is a egfr kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is solid which is soluble in DMSO (89 mg/ml at 25 °C), methanol (20 mg/ml), ethanol (4 mg/ml at 25 °C), DMF (20 mg/ml), and water (<1 mg/ml at 25 °C).

Gefitinib (EGFR Kinase inhibitor)

SIH-445-50MG 50 mg
EUR 164.4
Description: The substance Gefitinib is a egfr kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is solid which is soluble in DMSO (89 mg/ml at 25 °C), methanol (20 mg/ml), ethanol (4 mg/ml at 25 °C), DMF (20 mg/ml), and water (<1 mg/ml at 25 °C).

Axitinib (VEGFR kinase inhibitor)

SIH-494-10MG 10 mg
EUR 346.8
Description: The substance Axitinib is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to tan powder which is soluble to 25 mM in DMSO.

Casein Kinase II Inhibitor IV

HY-111378 10mM/1mL
EUR 590.4

STO 609 (CAMKK kinase inhibitor)

SIH-479-25MG 25 mg
EUR 474
Description: The substance STO 609 is a camkk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml).

STO 609 (CAMKK kinase inhibitor)

SIH-479-5MG 5 mg
EUR 181.2
Description: The substance STO 609 is a camkk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml).

ZM 306416 (VEGFR kinase inhibitor)

SIH-487-25MG 25 mg
EUR 474
Description: The substance ZM 306416 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (3 mg/ml) or ethanol (1 mg/ml).

ZM 306416 (VEGFR kinase inhibitor)

SIH-487-5MG 5 mg
EUR 178.8
Description: The substance ZM 306416 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (3 mg/ml) or ethanol (1 mg/ml).

Ruxolitinib (JAK kinase inhibitor)

SIH-509-25MG 25 mg
EUR 750
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).

Ruxolitinib (JAK kinase inhibitor)

SIH-509-5MG 5 mg
EUR 285.6
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).

AG490 (JAK-2 kinase inhibitor)

SIH-428-25MG 25 mg
EUR 339.6
Description: The substance AG490 is a jak-2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is tan solid which is soluble in DMSO (30 mg/ml), dimethyl formamide (40 mg/ml) or 100% ethanol (10 mg/ml).

AG490 (JAK-2 kinase inhibitor)

SIH-428-5MG 5 mg
EUR 158.4
Description: The substance AG490 is a jak-2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is tan solid which is soluble in DMSO (30 mg/ml), dimethyl formamide (40 mg/ml) or 100% ethanol (10 mg/ml).

WHI P131 (JAK3 kinase inhibitor)

SIH-485-10MG 10 mg
EUR 178.8
Description: The substance WHI P131 is a jak3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (~1 mg/ml), and DMF (~1 mg/ml).

WHI P131 (JAK3 kinase inhibitor)

SIH-485-50MG 50 mg
EUR 460.8
Description: The substance WHI P131 is a jak3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (~1 mg/ml), and DMF (~1 mg/ml).

Apigenin (Protein kinase inhibitor)

SIH-249-10MG 10 mg
EUR 127.2
Description: The substance Apigenin is a protein kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 50 mM in DMSO.

Apigenin (Protein kinase inhibitor)

SIH-249-50MG 50 mg
EUR 255.6
Description: The substance Apigenin is a protein kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 50 mM in DMSO.

ATM Kinase Inhibitor, KU-55933

1685-5 each
EUR 288

Adenosine Kinase Inhibitor (hydrate)

C5282-1 1 mg
EUR 134.4
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations.

Adenosine Kinase Inhibitor (hydrate)

C5282-10 10 mg
EUR 435.6
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations.

Adenosine Kinase Inhibitor (hydrate)

C5282-5 5 mg
EUR 360
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations.

Diacylglycerol Kinase Inhibitor I

50R-R59022 50 mg
EUR 289.2
Description: Diacylglycerol Kinase Inhibitor I chemical reference substance

Dorsomorphin (AMPK kinase inhibitor)

SIH-443-25MG 25 mg
EUR 514.8
Description: The substance Dorsomorphin is a ampk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (4 mg/ml, warm).

Dorsomorphin (AMPK kinase inhibitor)

SIH-443-5MG 5 mg
EUR 184.8
Description: The substance Dorsomorphin is a ampk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (4 mg/ml, warm).

Imatinib mesylate (Kinase inhibitor)

SIH-453-100MG 100 mg
EUR 279.6
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear .

Imatinib mesylate (Kinase inhibitor)

SIH-453-20MG 20 mg
EUR 151.2
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear .

BAY 11 7082 (IKK kinase inhibitor)

SIH-434-10MG 10 mg
EUR 184.8
Description: The substance BAY 11 7082 is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in ethanol and to 100 mM in DMSO.

BAY 11 7082 (IKK kinase inhibitor)

SIH-434-50MG 50 mg
EUR 507.6
Description: The substance BAY 11 7082 is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in ethanol and to 100 mM in DMSO.

PX 866 (PI 3-Kinase inhibitor)

SIH-471-1MG 1 mg
EUR 178.8
Description: The substance PX 866 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO at 200 mg/ml; soluble in ethanol at 200 mg/ml; very poorly soluble in water.

PX 866 (PI 3-Kinase inhibitor)

SIH-471-5MG 5 mg
EUR 298.8
Description: The substance PX 866 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO at 200 mg/ml; soluble in ethanol at 200 mg/ml; very poorly soluble in water.

LY 294002 (PI 3-Kinase inhibitor)

SIH-252-25MG 25 mg
EUR 532.8
Description: The substance LY 294002 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white crystalline solid which is soluble to 5 mM in ethanol and to 25 mM in DMSO.

Geef een reactie

Het e-mailadres wordt niet gepubliceerd. Vereiste velden zijn gemarkeerd met *